# Lyell Immunopharma, Inc. Common Stock (LYEL)

> Lyell Immunopharma, Inc. Common Stock (LYEL) trades at $15.08 (+0.53%) as of 1:43:39 PM EST on Nov 6, 2026, +72.81% over the past month. Market cap is $368.78M, with 7.8 days to cover in short interest.

Canonical: https://massive.com/quote/lyel
Data as of: 2026-11-06T18:43:39.354Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$15.08** +0.08 (+0.53%)
As of 1:43:39 PM EST on Nov 6, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Lyell Immunopharma, Inc. Common Stock (LYEL) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +1.27% |
| 1W | +37.59% |
| 1M | +72.81% |
| YTD | -50.65% |
| 1Y | -13.25% |
| 52-wk range | $7.20 – $45.00 |

From daily closes through Nov 6, 2026.

## Key statistics

Today's trading snapshot for LYEL: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $14.79 – $16.08 |
| Open | $15.75 |
| Prev close | $15.00 |
| Volume | 143.35K |
| Market cap | $368.78M |
| Shares out | 24.5M |

## Valuation and profitability ratios

Valuation and profitability ratios for Lyell Immunopharma, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 13658.65 |
| P/B | 1.58 |
| P/FCF | — |
| ROE | -106.3% |
| ROA | -79.9% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 5, 2026

## Insider trading

[Lyell Immunopharma, Inc. Common Stock (LYEL) insider trading](https://massive.com/quote/lyel/insider-trading.md): open-market Form 4 buys and sells by Lyell Immunopharma, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Lyell Immunopharma, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 4, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 4, 2026, Lyell Immunopharma, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026.”
- Nov 4, 2026 · Private placement
  “On November 3, 2026, Lyell Immunopharma, Inc. entered into a Securities Purchase Agreement with certain institutional accredited investors, pursuant to which the Company agreed to sell and issue an aggregate of 7,428,040 shares of the Company's common stock at a purchase price of $10.77 per Share, in a private placement transaction. The total gross proceeds from the Private Placement, before expenses, are expected to be approximately $80.0 million.”
- Sep 10, 2026 · Product or service launch
  “Lyell Immunopharma, Inc. issued a press release regarding "the completion of the technology transfer for LYL273 to the Company's LyFE Manufacturing Facility™ in Bothell, Washington" and described LYL273 as the Company's "next-generation guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate."”
- Mar 9, 2026 · Executive compensation change
  “Pursuant to the offer letter, Ms. Shah is entitled to receive an initial annual base salary of $500,000 and a target annual bonus of up to 50% of her base salary. In addition, Ms. Shah will receive a stock option for 140,000 shares of common stock of the Company, with an exercise price equal to the fair market value of the common stock on the date of grant, to be granted under the Company's 2021 Equity Incentive Plan.”
- Dec 8, 2025 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “Translational data from the ongoing Phase 1/2 clinical trial showed that ronde-cel manufactured with CD62L enrichment achieved robust expansion and high expression of memory-related genes after infusion in patients with LBCL. Ronde-cel had up to a three-fold higher expansion in patients after infusion compared to the expansion of approved CD19 CAR T-cell products.”

## Dividend history and stock splits

Lyell Immunopharma, Inc. Common Stock's recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-20 · Jun 2, 2025

## LYEL short interest

How heavily LYEL is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 7.8 |
| Short interest | 1.4M |
| Avg volume | 178.11K |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## LYEL news

The latest news and headlines about Lyell Immunopharma, Inc. Common Stock (LYEL).

- [Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress](https://www.globenewswire.com/news-release/2026/06/12/3311241/0/en/Lyell-Immunopharma-Presents-Updated-Safety-Data-and-Translational-Insights-for-Rondecabtagene-Autoleucel-Ronde-Cel-in-Patients-with-Large-B-Cell-Lymphoma-at-European-Hematology-Ass.html) · GlobeNewswire Inc. · Jun 12, 2026 · positive sentiment
- [Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion](https://www.globenewswire.com/news-release/2026/06/08/3307886/0/en/Lyell-Immunopharma-Provides-Update-on-Safety-Profile-of-LYL273-in-Relapsed-or-Refractory-Metastatic-Colorectal-Cancer-and-Amends-Phase-1-Trial-to-Phase-1-2-Expansion.html) · GlobeNewswire Inc. · Jun 8, 2026 · positive sentiment
- [Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer](https://www.globenewswire.com/news-release/2026/03/09/3251756/0/en/Lyell-Immunopharma-Announces-Closing-of-Additional-50-Million-Tranche-of-Equity-Private-Placement-and-Appointment-of-Smital-Shah-as-Chief-Financial-and-Business-Officer.html) · GlobeNewswire Inc. · Mar 9, 2026 · positive sentiment
- [Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors](https://www.globenewswire.com/news-release/2025/12/09/3202269/0/en/Century-Therapeutics-Appoints-Accomplished-Biotechnology-Leaders-Dr-Han-Lee-and-Dr-Martin-Murphy-to-Board-of-Directors.html) · GlobeNewswire Inc. · Dec 9, 2025 · positive sentiment
- [Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition](https://www.globenewswire.com/news-release/2025/12/07/3201148/0/en/Lyell-Immunopharma-Presents-New-Clinical-Data-from-Ongoing-Trial-of-Ronde-Cel-Showing-High-Rates-of-Durable-Complete-Responses-in-Patients-with-Large-B-cell-Lymphoma-at-the-67th-AS.html) · GlobeNewswire Inc. · Dec 7, 2025 · positive sentiment

## About Lyell Immunopharma, Inc. Common Stock

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 161 |
| Listed | Jun 17, 2021 |

[Company website](https://www.lyell.com)

## FAQ

### What is the Lyell Immunopharma, Inc. Common Stock (LYEL) stock price today?

Lyell Immunopharma, Inc. Common Stock (LYEL) is trading at $15.08 (+0.53% on the day) as of 1:43:39 PM EST on Nov 6, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Lyell Immunopharma, Inc. Common Stock?

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.

### What is the short interest in LYEL?

As of Oct 15, 2026, LYEL has 1.4M shares short and 7.8 days to cover.

### What exchange is LYEL listed on?

Lyell Immunopharma, Inc. Common Stock (LYEL) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time LYEL quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=LYEL`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Lyell Immunopharma, Inc. Common Stock (LYEL) insider trading](https://massive.com/quote/lyel/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms